Hoxworth

Clinical Research

The Research department assists companies with licensing studies for new products and validation studies where new procedures are tested before use in clinical studies. Some of the biomedical companies we collaborate with include: Astellas Gene Therapies (Audentes), Biolog-id, Cellphire, Cerus, CytoSorbents, Fresenius Kabi, Hemanext, Haemonetics, Teleflex, TerumoBCT, MacoPharmaUSA, MEQU, and Velico Medical. 

Expertise:

  1. Radioisotope labeling methods for measurement of red cell recovery and survival using chromium-51 and technetium-99m.
  2. Radioisotope labeling methods for measurement of platelet recovery and survival using chromium-51 and indium-111.
  3. Morphologic and functional tests of red blood cells including: adenosine 5’ triphosphate (ATP), 2,3 diphosphoglycerate (DPG), p50, supernatant hemoglobin, hemolysis, osmotic fragility, blood gases, glucose, sodium, potassium, lactate, morphology, rejuvenation of ATP and 2,3 DPG and flow-cytometric measurement of microparticles (microvesicles), annexin V and phosphotidylserine (PS).
  4. Evaluation of leukoreduced products including flow-cytometric, low event leukocyte counting and percent cell loss.
  5. Functional platelet test including: morphology, hypotonic shock response (HSR), extent of shape change (ESC), ATP, morphology, aggregation, lactate dehydrogenase and flow-cytometric measurement of CD62-P (P-selectin), annexin V microparticles, thromboelastography (TEG), lactate dehydrogenase (LDH), PS, and circulating platelet specific antibodies.
  6. Plasma analysis including: protein and coagulation assays.
  7. Evaluation of different automated blood collection systems/technologies.
  8. Pathogen reduction studies in blood components.

Compliance:

All studies are reviewed and approved by the Institutional Review Board of the University of Cincinnati Medical Center and Radiation Safety where applicable. Current Good Manufacturing Practices are followed in performance of all procedures, and the laboratory meets the standards of all sponsors as determined by on-site inspections.

Selected Publications:

  1. Cancelas JA, Slichter SJ, Rugg N, Pratt PG, Nestheide S, Corson J, Pellham E, Huntington M, Goodrich RP. Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storagev. Transfusion 2017 May;57(5):1218-25. PMID 28369971.
  2. Cancelas JA, Gottschall JL, Rugg N, Graminske S, Schott MA, North A, Huang N, Mufti N, Rico S, Corash L. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang 2017 Apr;112(3)210-8. PMID 28220519 (Erratum: Vox Sang 2017 Jul;112(5):495 PMID 28727151)
  3. Cancelas JA, Rugg N, Nestheide S, Hill SE, Gorgas GD, Emanuele RM, McKenzie DS. The purified vepoloxamer, prevents hemolysis in 42-day stored, DEHP/PVC-free RBC units. Blood Transfus 2017 Mar;15 (2):165-71. PMID 28263175, PMC5336339
  4. Cancelas JA, Scott EP, Bill JR. Continuous CD34+ cell collection by a new device is safe and more efficient than by a standard collection procedure: results of a two-center, crossover, randomized trial. Transfusion 2016 Nov;56(11):2824-32. PMID 27589225
  5. Cancelas JA, Padmanabhan A, Le T, Ambruso DR, Rugg N, et al. Spectra Optia granulocyte apheresis collections result in higher collection efficiency of viable, functional neutrophils in a randomized, crossover, multicenter trial. Transfusion, 2015 Apr;55(4):748-55. PMID 25382805

For more information please contact Neeta Rugg (Assistant Director, Research) at (513) 558-1525.